All Articles

Patients diagnosed with major diseases, including cancer, often experience financial hardship due to high out-of-pocket medical costs in the United States. Read More ›

Increased access to broadband usage was associated with earlier-stage non-small cell lung cancer diagnosis and with receiving guideline-concordant care in 2020, during the height of the COVID-19 pandemic. Read More ›

Officials with the FDA recently approved the menin inhibitor revumenib (Revuforj; Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene translocation. Read More ›

The CD19-directed genetically modified autologous T-cell immunotherapy, obecabtagene autoleucel (Aucatazyl; Autolus Inc.), has been approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More ›

Asciminib (Scemblix; Novartis AG) has been approved for use in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Read More ›

Officials with the Food and Drug Administration have approved zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.) Read More ›

This feature examines some of the cutting-edge trials that have been launched throughout 2024 and that are actively recruiting in breast cancer. Read More ›

Two quadruplet therapies have been approved by the FDA as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) and updated in the NCCN guidelines for the treatment of multiple myeloma. Read More ›

This article summarizes results of the phase 3 IMROZ study, including the frailty subgroup analysis. Read More ›

Results of the BENEFIT study provide evidence that a weekly bortezomib regimen in isatuximab plus bortezomib, lenalidomide, and dexamethasone can be an effective and feasible option for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). Read More ›